CNTB Stock Analysis: Buy, Sell, or Hold?
CNTB - Connect Biopharma Holdings Limited Ordinary Shares
$2.45
0.19 (8.41%)
▲
5d:
+10.86%
30d:
+16.67%
90d:
-13.43%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 12, 2026
28d
Get Alerted When CNTB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called CNTB this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CNTB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CNTB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CNTB is currently trading at $2.45, which is considered extended relative to its 30-day fair value range of $2.04 to $2.40.
Technical Outlook: Technically, CNTB is in a downtrend. The price is approaching resistance at $2.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.4% recently.
Market Sentiment: CNTB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.12 (+215.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CNTB is in a downtrend. The price is approaching resistance at $2.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.4% recently.
Market Sentiment: CNTB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.12 (+215.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.04 -
$2.40
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
68.4%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.4%)
- BULLISH: Trading 215.3% below Wall St target ($7.12)
Trading Range Analysis
30-Day Trading Range
$2.04 -
$2.40
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.93
Resistance Level
$2.29
Current Trend
Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.41
Wall Street Target
$7.13
(+215.3%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 14, 2026 2:59 PM ET
Data refreshes hourly during market hours. Next update: 3:59 PM
Data refreshes hourly during market hours. Next update: 3:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTB showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
James Huang
BUY
1160000 shares
2026-03-31
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 58 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 64 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 55 HOLD |
